Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,221JPY
1:00am EST
Change (% chg)

¥-53 (-0.84%)
Prev Close
¥6,274
Open
¥6,264
Day's High
¥6,277
Day's Low
¥6,201
Volume
2,629,700
Avg. Vol
1,998,022
52-wk High
¥6,464
52-wk Low
¥4,664

Latest Key Developments (Source: Significant Developments)

Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion
7:11am EST 

Dec 15 (Reuters) - TIGENIX NV ::REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE.‍FIRST ALLOGENEIC STEM CELL THERAPY TO RECEIVE POSITIVE CHMP OPINION IN EUROPE​.‍CX601 OFFERS POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WHO DO NOT RESPOND TO CURRENT AVAILABLE THERAPIES AND ARE SUBJECT TO NUMEROUS INVASIVE SURGERIES​.‍RECEIPT OF MA WILL TRIGGER A MILESTONE PAYMENT FROM TAKEDA TO TIGENIX OF EUR 15 MILLION​.  Full Article

Obsidian Therapeutics Announces $49.5 Mln Series A Financing To Develop Controllable Cell And Gene Therapy Products
Wednesday, 6 Dec 2017 06:15am EST 

Dec 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::OBSIDIAN THERAPEUTICS ANNOUNCES $49.5 MILLION SERIES A FINANCING TO DEVELOP CONTROLLABLE CELL AND GENE THERAPY PRODUCTS.OBSIDIAN THERAPEUTICS - SERIES A FINANCING LED BY GV, AND INCLUDED TAKEDA VENTURES, AMGEN VENTURES AMONG OTHERS.  Full Article

Takashimaya to acquire Tokyo-based real estate properties for 49.5 bln yen
Friday, 1 Dec 2017 02:22am EST 

Dec 1 (Reuters) - Takashimaya Co Ltd <8233.T>:Says it signs agreement with a wholly owned unit of Takeda Pharmaceutical Co Ltd <<<4502.T>>>, to acquire two Tokyo-based real estate properties as of the end of March 2019, at the price of 49.5 billion yen in total.  Full Article

Takeda Pharmaceutical unit signs agreement for sale of properties worth 49.5 bln yen
Friday, 1 Dec 2017 02:04am EST 

Dec 1(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says its wholly owned subsidiary Takeda Pharmaceutical Real Estate Company has signed an agreement with Takashimaya Company Limited for the sale of properties.Says the sale price is 49.5 billion yen.  Full Article

Takeda Initiates Phase 1 Clinical Trial Of Zika Vaccine Candidate
Tuesday, 28 Nov 2017 08:02am EST 

Nov 28 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA INITIATES PHASE 1 CLINICAL TRIAL OF ZIKA VACCINE CANDIDATE.SAYS ITS ‍ZIKA VIRUS VACCINE CANDIDATE (TAK-426) HAS PROGRESSED INTO A PHASE 1 CLINICAL TRIAL​.  Full Article

U.S. FDA provides new drug safety communication on Takeda's gout drug
Wednesday, 15 Nov 2017 01:32pm EST 

Nov 15 (Reuters) - U.S. Food and Drug Administration : :U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol.U.S. FDA says once final results from Takeda Pharma are received in relation to safety clinical trial of Uloric, will conduct a comprehensive review.  Full Article

TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA
Tuesday, 14 Nov 2017 10:00am EST 

Nov 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍CHMP POSITIVE OPINION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​.‍EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINION FOR EXTENSION OF MARKETING AUTHORIZATION OF ADCETRIS​.‍CHMP RECOMMENDED ADCETRIS​ ITS APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍SEATTLE GENETICS AND TAKEDA ARE JOINTLY DEVELOPING ADCETRIS​.  Full Article

Takeda and HemoShear Therapeutics enter drug discovery partnership in liver diseases
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Takeda and HemoShear Therapeutics enter into exclusive drug discovery partnership in liver diseases.Takeda - HemoShear to get upfront payments and research and development funding, and is also eligible to get milestone payments of potentially $470 million and royalties​.Takeda Pharmaceutical Co Ltd - ‍further financial terms were not disclosed​.  Full Article

Takeda presents updated results from pivotal phase 2 ALTA trial of ALUNBRIGTM
Monday, 16 Oct 2017 02:45am EDT 

Oct 16 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::Takeda presents updated results from pivotal phase 2 ALTA trial of ALUNBRIGTM (brigatinib) in alk-positive non-small cell lung cancer.Takeda Pharmaceutical Co Ltd says ‍confirmed objective response rate, which was primary endpoint, was 46 percent in arm a and 55 percent in arm b​.Takeda pharmaceutical co ltd says ‍efficacy and safety data from alta trial continue to support future trials with 180 mg dosing regimen​.Takeda pharmaceutical co ltd says ‍median overall survival os was not reached in arm a and 27.6 months in arm b​.  Full Article

Takeda gets FDA approval for ALUNBRIG 180 mg tablets
Tuesday, 3 Oct 2017 08:00am EDT 

Oct 3 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Takeda announces FDA approval of ALUNBRIG (brigatinib) 180 mg tablets.Takeda Pharmaceutical Co Ltd - 180 mg tablets and previously approved 90 mg tablets will be available later this year.  Full Article

Photo

Amgen's Kyprolis improves overall survival in blood cancer patients

Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.